LONDON / Jul 09, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LONDON / Jun 05, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study , evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the... Read More

This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LONDON / Jun 05, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with... Read More

Final critical papers on RECOVER clinical study data accepted, supporting the Company’s submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yields positive results LONDON / Jun 04, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it... Read More

LONDON / May 15, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend... Read More

Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data... Read More

Top-line results at 12 months of treatment show meaningful improvement over time: Overall responder rate of 65% Overall reduction in median apnea-hypopnea index of 68% Overall reduction in median oxygen desaturation index of 68% LONDON / May 07, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial... Read More

LONDON / Mar 26, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

LONDON / Feb 25, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights (1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period... Read More

LONDON / Feb 21, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to... Read More

LONDON / Jan 21, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events.... Read More

Results published in two articles in Brain Stimulation LONDON / Dec 18, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study . The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its... Read More

LONDON / Dec 05, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support a deeper understanding of the... Read More

LONDON / Nov 14, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December: Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11:30 a.m. - 12:00 p.m. Eastern Time, 6 th... Read More

Top-line results compared to baseline at six months: Median apnea-hypopnea index reduction of 66.2% Median oxygen desaturation index reduction of 63.3% LONDON / Nov 11, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal... Read More

LONDON / Oct 30, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights (1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the... Read More

LONDON / Oct 08, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. “LivaNova’s Board of Directors is pleased to welcome Susan Podlogar,” said William Kozy, Chair of the Board. “Susan is a... Read More

LONDON / Sep 25, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

LONDON / Aug 19, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation will take place at 10:15 a.m. Eastern Time on Tuesday, September 10. The discussion will be available to all interested parties who register to... Read More

LONDON / Jul 31, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the... Read More

LONDON / Jun 18, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LONDON / Jun 06, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study... Read More

LONDON / May 23, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida. The presentation will take place at 1:20 p.m. Eastern Time on Monday, June 10. The discussion will be available to all interested parties who register to... Read More

LONDON / May 01, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to... Read More

LONDON / Apr 30, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will... Read More

LONDON / Apr 25, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems.... Read More

LONDON / Mar 21, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

LONDON / Mar 20, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully... Read More

LONDON / Mar 05, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the... Read More

LONDON / Mar 04, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities... Read More

LONDON / Mar 04, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 10:45 a.m. Eastern Time on Tuesday, March 12. The discussion will be available to all interested parties who register to... Read More

LONDON / Feb 21, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights 1 Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period... Read More

William Kozy will remain Board Chair LONDON / Feb 05, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024. Makatsaria most recently served as Company Group Chairman at Johnson & Johnson MedTech, leading... Read More

Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LONDON / Jan 08, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS) Business Unit to... Read More

LONDON / Jan 04, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events... Read More

LONDON / Nov 09, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Piper Sandler Healthcare Conference in New York. The presentation will take place at 8:30 a.m. Eastern Time on Wednesday, November 29. The discussion will be available to all interested... Read More

LONDON / Nov 01, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights 1 Third-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as... Read More

LONDON / Oct 25, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November: Stifel Healthcare Conference 2023 on Tuesday, November 14 from 9:10 - 9:40 a.m. ET 5 th Annual Wolfe Research... Read More

Long-time Director Andrea Saia to retire from the Board LONDON / Oct 06, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December... Read More

LONDON / Sep 21, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023. Dolci will continue in his role and support the transition of responsibilities through the end of the year. Franco Poletti will serve as Interim General Manager of CP to support the... Read More

LONDON / Sep 20, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should log on... Read More

LONDON / Aug 30, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM) , which provides accurate and continuous measurement of essential blood... Read More

LONDON / Aug 24, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Baird Global Healthcare Conference in New York. The presentation will take place at 12:50 p.m. Eastern Time on Tuesday, September 12. The discussion will be available to all interested... Read More

LONDON / Jul 26, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a constant-currency basis, as compared to the prior-year period Second quarter U.S.... Read More

LONDON / Jun 14, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2023 results on Wednesday, July 26, 2023 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners... Read More

LONDON / Jun 13, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 150th bipolar depression patient has been randomized in the RECOVER clinical study , “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem o nstrating the Safety and Effectiveness of V NS Therapy™ System as Adjunctiv e Therapy Versus a No Stimulation Control... Read More

LONDON / May 03, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights 1 First-quarter revenue of $263.4 million increased 9.7 percent on a reported basis and increased 12.7 percent on a constant-currency basis, as compared to the prior-year... Read More

LONDON / Apr 14, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effective immediately, Chair of the Board William A. Kozy is appointed interim CEO to help the executive leadership team maintain the focus on growth and profitability. The Board has retained a leading international... Read More

LONDON / Mar 22, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should... Read More

LONDON / Mar 09, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the... Read More

LONDON / Mar 09, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 9 a.m. Eastern Time on Thursday, March 16. The discussion will be available to all interested parties who... Read More

LONDON / Feb 22, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023. Fourth-Quarter Financial Summary and Highlights 1 Fourth-quarter revenue of $274.9 million increased 1.8 percent on a reported basis and 6.2 percent on a constant-currency basis, as compared... Read More

LONDON / Feb 08, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has been initiated in select centers throughout Europe, following a successful clinical experience in two major centers, Catharina Hospital in Eindhoven, Netherlands and San Donato Hospital in... Read More

New device expands access to the latest technology for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S. LONDON / Feb 02, 2023 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO™, an implantable pulse generator (IPG) with a... Read More

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February 22, 2023 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2022 results prior to the call. A live audiocast will be accessible at www.livanova.com/events . Listeners should log... Read More